Fluoxetine
Generic name: Pronounced as (floo ox' e teen)
Medical Content Reviewed By HelloPharmacist Staff
Last Revised - 01/15/2022
On this page
- Why is this medication prescribed?
- How should this medicine be used?
- Other uses for this medicine
- What special precautions should I follow?
- What should I do if I forget a dose?
- What side effects can this medication cause?
- What should I know about STORAGE and DISPOSAL of this medication?
- What should I do in case of OVERDOSE?
- What OTHER INFORMATION should I know?
- Brand names of combination products
- Drug interactions
IMPORTANT WARNING
A small number of children, teenagers, and young adults (up to 24 years of age) who took antidepressants ('mood elevators') such as fluoxetine during clinical studies became suicidal (thinking about harming or killing oneself or planning or trying to do so). Children, teenagers, and young adults who take antidepressants to treat depression or other mental illnesses may be more likely to become suicidal than children, teenagers, and young adults who do not take antidepressants to treat these conditions. However, experts are not sure about how great this risk is and how much it should be considered in deciding whether a child or teenager should take an antidepressant.
You should know that your mental health may change in unexpected ways when you take fluoxetine or other antidepressants even if you are an adult over 24 years of age. You may become suicidal, especially at the beginning of your treatment and any time that your dose is increased or decreased. You, your family, or your caregiver should call your doctor right away if you experience any of the following symptoms: new or worsening depression; thinking about harming or killing yourself, or planning or trying to do so; extreme worry; agitation; panic attacks; difficulty falling asleep or staying asleep; aggressive behavior; irritability; acting without thinking; severe restlessness; and frenzied abnormal excitement. Be sure that your family or caregiver knows which symptoms may be serious so they can call the doctor if you are unable to seek treatment on your own.
Your healthcare provider will want to see you often while you are taking fluoxetine, especially at the beginning of your treatment. Be sure to keep all appointments for office visits with your doctor.
The doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with fluoxetine. Read the information carefully and ask your doctor or pharmacist if you have any questions. You also can obtain the Medication Guide from the FDA website: http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm.
No matter your age, before you take an antidepressant, you, your parent, or your caregiver should talk to your doctor about the risks and benefits of treating your condition with an antidepressant or with other treatments. You should also talk about the risks and benefits of not treating your condition. You should know that having depression or another mental illness greatly increases the risk that you will become suicidal. This risk is higher if you or anyone in your family has or has ever had bipolar disorder (mood that changes from depressed to abnormally excited) or mania (frenzied, abnormally excited mood) or has thought about or attempted suicide. Talk to your doctor about your condition, symptoms, and personal and family medical history. You and your doctor will decide what type of treatment is right for you.
Why is this medication prescribed?
Fluoxetine is used to treat depression, obsessive-compulsive disorder (bothersome thoughts that won't go away and the need to perform certain actions over and over), some eating disorders, and panic attacks (sudden, unexpected attacks of extreme fear and worry about these attacks). Fluoxetine is also used to relieve the symptoms of premenstrual dysphoric disorder, including mood swings, irritability, bloating, and breast tenderness. It is also used along with olanzapine (Zyprexa) to treat depression that did not respond to other medications and episodes of depression in people with bipolar I disorder (manic-depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Fluoxetine is in a class of medications called selective serotonin reuptake inhibitors (SSRIs). It works by increasing the amount of serotonin, a natural substance in the brain that helps maintain mental balance.
How should this medicine be used?
Fluoxetine comes as a capsule, a tablet, a delayed-release (releases the medication in the intestine) capsule, and a solution (liquid) to take by mouth. Fluoxetine may be taken with or without food. Fluoxetine capsules, tablets, and liquid are usually taken once a day in the morning or twice a day in the morning and at noon. Fluoxetine delayed-released capsules are usually taken once a week. Take fluoxetine at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take fluoxetine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Swallow the delayed-release capsules whole; do not cut, crush, or chew them.
Your doctor may start you on a low dose of fluoxetine and gradually increase your dose.
It may take 4 to 5 weeks or longer before you feel the full benefit of fluoxetine. Continue to take fluoxetine even if you feel well. Do not stop taking fluoxetine without talking to your doctor. If you suddenly stop taking fluoxetine, you may experience withdrawal symptoms such as mood changes, irritability, agitation, dizziness, numbness or tingling in the hands or feet, anxiety, sweating, confusion, headache, tiredness, and difficulty falling asleep or staying asleep. Your doctor will probably decrease your dose gradually.
Other uses for this medicine
Fluoxetine is also sometimes used to treat alcoholism, attention-deficit disorder, borderline personality disorder, sleep disorders, headaches, mental illness, posttraumatic stress disorder, Tourette's syndrome, obesity, sexual problems, and phobias. Talk to your doctor about the possible risks of using this medication for your condition.
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before taking fluoxetine,
-
tell your doctor and pharmacist if you are allergic to fluoxetine, any other medications, or any of the ingredients in fluoxetine capsules, tablets, or solution. Ask your pharmacist for a list of the ingredients.
-
tell your doctor if you are taking pimozide (Orap), thioridazine, or a monoamine oxidase (MAO) inhibitor such as isocarboxazid (Marplan), linezolid (Zyvox), methylene blue, phenelzine (Nardil), selegiline (Emsam, Zelapar), and tranylcypromine (Parnate), or if you have stopped taking a monoamine oxidase inhibitor within the past 2 weeks. Your doctor will probably tell you that you should not take fluoxetine. If you stop taking fluoxetine, you should wait at least 5 weeks before you begin to take thioridazine or a monoamine oxidase inhibitor.
-
tell your doctor and pharmacist what other prescription and nonprescription medications and vitamins you are taking or plan to take. Be sure to mention any of the following: alprazolam (Xanax); amiodarone (Pacerone, Nexterone); certain antibiotics such as erythromycin (E.E.S, Eryc, Ery-tab), gatifloxacin, moxifloxacin (Avelox), and sparfloxacin (no longer available in U.S., Zagam); amphetamines such as amphetamine (in Adderall), dextroamphetamine (Dexedrine, Dextrostat, in Adderall), and methamphetamine (Desoxyn); anticoagulants ('blood thinners') such as warfarin (Coumadin, Jantoven); antidepressants (mood elevators) such as amitriptyline, amoxapine, clomipramine (Anafranil), desipramine (Norpramin), doxepin, imipramine (Tofranil), nortriptyline (Pamelor), protriptyline, and trimipramine; aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin) and naproxen (Aleve, Naprosyn); buspirone; clopidogrel (Plavix); diazepam (Valium, Valtoco); digoxin (Lanoxin); diuretics ('water pills'); dolasetron (Anzemet); fentanyl (Fentora, Lazanda, Subsys, others); flecainide; insulin or oral medications for diabetes; lithium (Lithobid); medications for anxiety and Parkinson's disease; medications for mental illness such as chlorpromazine, clozapine (Clozaril, Versacloz), droperidol (Inapsine), haloperidol (Haldol), iloperidone (Fanapt), and ziprasidone (Geodon); methadone (Methadose); medications for migraine headaches such as almotriptan, eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt), sumatriptan (Imitrex), and zolmitriptan (Zomig); pentamidine (Pentam); quinidine (in Nuedexta); procainamide; medications for seizures such as carbamazepine (Epitol, Equetro, Tegretol, Teril) and phenytoin (Dilantin, Phenytek); sedatives; sleeping pills; other selective serotonin-reuptake inhibitors such as citalopram (Celexa), or fluvoxamine (Luvox), paroxetine (Paxil), or sertraline (Zoloft); serotonin–norepinephrine reuptake inhibitors (SNRI) medications desvenlafaxine (Khedezla, Pristiq), duloxetine (Cymbalta), levomilnacipran (Fetzima), and venlafaxine; sotalol (Betapace, Sorine); tramadol (Conzip, Qdolo, Ultram, in Ultracet); tranquilizers; and vinblastine. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
-
tell your doctor what nutritional supplements and herbal products you are taking, especially products that contain St. John's wort or tryptophan.
-
tell your doctor if you or anyone in your family has or has ever had a prolonged QT interval (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death). Also tell your doctor if you have a low level of potassium, magnesium, or sodium in your blood or are being treated with electroshock therapy (procedure in which small electric shocks are administered to the brain to treat certain mental illnesses). Tell your doctor if you have recently had a heart attack and if you have or have ever had a slow or irregular heartbeat, heart failure, or any other heart problems; high blood pressure; bleeding problems; a stroke; diabetes; seizures; or liver or kidney disease.
-
tell your doctor if you are pregnant, especially if you are in the last few months of your pregnancy, or if you plan to become pregnant or are breastfeeding. If you become pregnant while taking fluoxetine, call your doctor. Fluoxetine may cause problems in newborns following delivery if it is taken during the last months of pregnancy.
-
you should know that fluoxetine may make you drowsy and may affect your judgment, thinking, and movements. Do not drive a car or operate machinery until you know how this medication affects you.
-
remember that alcohol can add to the drowsiness caused by this medication.
-
you should know that fluoxetine may cause angle-closure glaucoma (a condition where the fluid is suddenly blocked and unable to flow out of the eye causing a quick, severe increase in eye pressure which may lead to a loss of vision). Talk to your doctor about having an eye examination before you start taking this medication. If you have nausea, eye pain, changes in vision, such as seeing colored rings around lights, and swelling or redness in or around the eye, call your doctor or get emergency medical treatment right away.
What should I do if I forget a dose?
Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
What side effects can this medication cause?
-
Fluoxetine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
-
nervousness
-
anxiety
-
difficulty falling asleep or staying asleep
-
nausea
-
diarrhea
-
dry mouth
-
heartburn
-
yawning
-
weakness
-
uncontrollable shaking of a part of the body
-
loss of appetite
-
weight loss
-
unusual dreams
-
stuffy nose
-
sexual problems in males; decreased sex drive, inability to get or keep an erection, or delayed or absent ejaculation
-
sexual problems in females; decreased sex drive, or delayed orgasm or unable to have an orgasm
-
excessive sweating
-
headache, confusion, weakness, difficulty concentrating, or memory problems
-
-
Some side effects can be serious. If you experience any of the following symptoms or those listed in the IMPORTANT WARNING or SPECIAL PRECAUTIONS section, call your doctor immediately:
-
rash
-
hives or blisters
-
itching
-
fever
-
joint pain
-
swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs
-
difficulty breathing or swallowing
-
agitation, fever, sweating, confusion, fast or irregular heartbeat, shivering, severe muscle stiffness or twitching, hallucinations, loss of coordination, nausea, vomiting, or diarrhea
-
fast, slow, or irregular heartbeat
-
shortness of breath
-
dizziness or fainting
-
seizures
-
abnormal bleeding or bruising
-
-
Fluoxetine may decrease appetite and cause weight loss in children. Your child's doctor will watch his or her growth carefully. Talk to your child's doctor if you have concerns about your child's growth or weight while he or she is taking this medication. Talk to your child's doctor about the risks of giving fluoxetine to your child.
-
Fluoxetine may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.
-
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).
What should I know about STORAGE and DISPOSAL of this medication?
Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from light, excess heat, and moisture (not in the bathroom).
It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org
Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.
What should I do in case of OVERDOSE?
In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.
Symptoms of overdose may include the following:
-
unsteadiness
-
confusion
-
unresponsiveness
-
nervousness
-
uncontrollable shaking of a part of the body
-
dizziness
-
rapid, irregular, or pounding heartbeat
-
seeing things or hearing voices that do not exist (hallucinating)
-
fever
-
fainting
-
seizures
-
coma (loss of consciousness for a period of time)
What OTHER INFORMATION should I know?
Keep all appointments with your doctor.
Before having any laboratory test (especially those that involve methylene blue), tell your doctor and the laboratory personnel that you are taking fluoxetine.
Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
Drug interactions
Drug | Interaction |
---|---|
Moxifloxacin | Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Fluoxetine. |
Repaglinide | Repaglinide The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Repaglinide. |
Montelukast | Montelukast The metabolism of Montelukast can be decreased when combined with Fluoxetine. |
Insulin Glargine (rDNA origin) Injection | Insulin Glargine (rDNA origin) Injection The metabolism of Fluoxetine can be increased when combined with Insulin glargine. |
Leflunomide | Leflunomide The serum concentration of Fluoxetine can be decreased when it is combined with Leflunomide. |
Delavirdine | Delavirdine The serum concentration of Fluoxetine can be increased when it is combined with Delavirdine. |
Nevirapine | Nevirapine The serum concentration of Nevirapine can be increased when it is combined with Fluoxetine. |
Dolasetron | Dolasetron The serum concentration of Dolasetron can be increased when it is combined with Fluoxetine. |
Aminophylline | Aminophylline The metabolism of Aminophylline can be decreased when combined with Fluoxetine. |
Anagrelide | Anagrelide The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Fluoxetine. |
Bisacodyl | Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Fluoxetine. |
Candesartan | Candesartan The metabolism of Candesartan can be decreased when combined with Fluoxetine. |
Cilostazol | Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Fluoxetine. |
Clopidogrel | Clopidogrel The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Fluoxetine resulting in a loss in efficacy. |
Diphenoxylate | Diphenoxylate The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Fluoxetine. |
Erythromycin and Sulfisoxazole | Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Fluoxetine. |
Estrogen and Progestin (Oral Contraceptives) | Estrogen and Progestin (Oral Contraceptives) The metabolism of Fluoxetine can be decreased when combined with Conjugated estrogens. |
Fenofibrate | Fenofibrate The metabolism of Fluoxetine can be decreased when combined with Fenofibrate. |
Guanfacine | Guanfacine Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Magnesium Hydroxide | Magnesium Hydroxide The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Fluoxetine. |
Magnesium Oxide | Magnesium Oxide The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Fluoxetine. |
Miglitol | Miglitol The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Miglitol. |
Naratriptan | Naratriptan The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Fluoxetine. |
Olsalazine | Olsalazine The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Olsalazine. |
Paregoric | Paregoric The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Morphine. |
Penbutolol | Penbutolol The serum concentration of Acebutolol can be increased when it is combined with Fluoxetine. |
Pentazocine | Pentazocine The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Fluoxetine. |
Polyethylene glycol-electrolyte solution (PEG-ES) | Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Fluoxetine. |
Psyllium | Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Fluoxetine. |
Ranitidine | Ranitidine The metabolism of Ranitidine can be decreased when combined with Fluoxetine. |
Reserpine | Reserpine Reserpine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Rizatriptan | Rizatriptan The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Rizatriptan. |
Sumatriptan | Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Fluoxetine. |
Tacrolimus | Tacrolimus The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Tacrolimus. |
Tizanidine | Tizanidine Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Zolmitriptan | Zolmitriptan The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Fluoxetine. |
Famotidine Injection | Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Fluoxetine. |
Fluconazole Injection | Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Fluoxetine. |
Foscarnet Injection | Foscarnet Injection The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Foscarnet. |
Hydromorphone Injection | Hydromorphone Injection The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Fluoxetine. |
Interferon Beta-1b Injection | Interferon Beta-1b Injection The metabolism of Fluoxetine can be decreased when combined with Interferon beta-1b. |
Interferon Gamma-1b Injection | Interferon Gamma-1b Injection The metabolism of Fluoxetine can be decreased when combined with Interferon gamma-1b. |
Levofloxacin Injection | Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Fluoxetine. |
Meperidine Injection | Meperidine Injection The serum concentration of Meperidine can be increased when it is combined with Fluoxetine. |
Metoclopramide Injection | Metoclopramide Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Fluoxetine. |
Metronidazole Injection | Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Fluoxetine. |
Morphine Injection | Morphine Injection The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Morphine. |
Zidovudine Injection | Zidovudine Injection The metabolism of Zidovudine can be decreased when combined with Fluoxetine. |
Altretamine | Altretamine The serum concentration of Amphetamine can be increased when it is combined with Fluoxetine. |
Cyclosporine | Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Fluoxetine. |
Ondansetron | Ondansetron The serum concentration of Ondansetron can be increased when it is combined with Fluoxetine. |
Enoxaparin Injection | Enoxaparin Injection The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Enoxaparin. |
Granisetron | Granisetron The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Fluoxetine. |
Torsemide | Torsemide The metabolism of Torasemide can be decreased when combined with Fluoxetine. |
Alosetron | Alosetron Alosetron may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Dofetilide | Dofetilide The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Fluoxetine. |
Entacapone | Entacapone Entacapone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Hydroxychloroquine | Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Fluoxetine. |
Meloxicam | Meloxicam The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Meloxicam. |
Oxcarbazepine | Oxcarbazepine Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Pantoprazole | Pantoprazole The metabolism of Pantoprazole can be decreased when combined with Fluoxetine. |
Telmisartan | Telmisartan The metabolism of Fluoxetine can be decreased when combined with Telmisartan. |
Zaleplon | Zaleplon Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Anakinra | Anakinra The metabolism of Fluoxetine can be increased when combined with Anakinra. |
Desloratadine | Desloratadine Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Linezolid | Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Fluoxetine. |
Pentosan Polysulfate | Pentosan Polysulfate The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Pentosan polysulfate. |
Rivastigmine | Rivastigmine The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Rivastigmine. |
Trimipramine | Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Fluoxetine. |
Etanercept Injection | Etanercept Injection The metabolism of Fluoxetine can be increased when combined with Etanercept. |
Glycopyrrolate | Glycopyrrolate Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium. |
Modafinil | Modafinil The metabolism of Fluoxetine can be decreased when combined with Modafinil. |
Choline Magnesium Trisalicylate | Choline Magnesium Trisalicylate The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Choline magnesium trisalicylate. |
Epinephrine Injection | Epinephrine Injection The metabolism of Fluoxetine can be decreased when combined with Epinephrine. |
Escitalopram | Escitalopram The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Escitalopram. |
Zonisamide | Zonisamide Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide. |
Adalimumab Injection | Adalimumab Injection The metabolism of Fluoxetine can be increased when combined with Adalimumab. |
Aripiprazole | Aripiprazole The serum concentration of Fluoxetine can be increased when it is combined with Aripiprazole. |
Atomoxetine | Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Fluoxetine. |
Dexmethylphenidate | Dexmethylphenidate The risk or severity of serotonin syndrome can be increased when Dexmethylphenidate is combined with Fluoxetine. |
Teriparatide Injection | Teriparatide Injection The therapeutic efficacy of Teriparatide can be decreased when used in combination with Fluoxetine. |
Atazanavir | Atazanavir The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Atazanavir. |
Almotriptan | Almotriptan The serum concentration of Almotriptan can be increased when it is combined with Fluoxetine. |
Eletriptan | Eletriptan The serum concentration of Eletriptan can be increased when it is combined with Fluoxetine. |
Mefloquine | Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Fluoxetine. |
Polyethylene Glycol 3350 | Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Fluoxetine. |
Rosuvastatin | Rosuvastatin The metabolism of Rosuvastatin can be decreased when combined with Fluoxetine. |
Vardenafil | Vardenafil The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Vardenafil. |
Alfuzosin | Alfuzosin The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Alfuzosin. |
Aprepitant | Aprepitant The metabolism of Fluoxetine can be decreased when combined with Aprepitant. |
Interferon Beta-1a Subcutaneous Injection | Interferon Beta-1a Subcutaneous Injection The metabolism of Fluoxetine can be decreased when combined with Interferon beta-1a. |
Memantine | Memantine The metabolism of Fluoxetine can be decreased when combined with Memantine. |
Tegaserod | Tegaserod The serum concentration of Tegaserod can be increased when it is combined with Fluoxetine. |
Frovatriptan | Frovatriptan The risk or severity of serotonin syndrome can be increased when Frovatriptan is combined with Fluoxetine. |
Gemifloxacin | Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Fluoxetine. |
Progesterone | Progesterone The serum concentration of Progesterone can be increased when it is combined with Fluoxetine. |
Apomorphine Injection | Apomorphine Injection The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Fluoxetine. |
Infliximab Injection | Infliximab Injection The metabolism of Fluoxetine can be increased when combined with Infliximab. |
Oxandrolone | Oxandrolone The metabolism of Fluoxetine can be decreased when combined with Oxandrolone. |
Protriptyline | Protriptyline The serum concentration of Fluoxetine can be increased when it is combined with Protriptyline. |
Rifaximin | Rifaximin The metabolism of Fluoxetine can be increased when combined with Rifaximin. |
Duloxetine | Duloxetine The serum concentration of Duloxetine can be increased when it is combined with Fluoxetine. |
Trospium | Trospium Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Trospium. |
Bosentan | Bosentan The metabolism of Bosentan can be decreased when combined with Fluoxetine. |
Cinacalcet | Cinacalcet The metabolism of Fluoxetine can be decreased when combined with Cinacalcet. |
Erlotinib | Erlotinib The serum concentration of Erlotinib can be increased when it is combined with Fluoxetine. |
Eszopiclone | Eszopiclone The risk or severity of CNS depression can be increased when Fluoxetine is combined with Eszopiclone. |
Insulin Aspart (rDNA Origin) Injection | Insulin Aspart (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Insulin aspart. |
Solifenacin | Solifenacin The serum concentration of Fluoxetine can be increased when it is combined with Solifenacin. |
Voriconazole | Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Fluoxetine. |
Dextroamphetamine | Dextroamphetamine The serum concentration of Amphetamine can be increased when it is combined with Fluoxetine. |
Entecavir | Entecavir The metabolism of Fluoxetine can be decreased when combined with Entecavir. |
Peginterferon Alfa-2a Injection | Peginterferon Alfa-2a Injection The metabolism of Fluoxetine can be decreased when combined with Peginterferon alfa-2a. |
Peginterferon Alfa-2b (PEG-Intron) | Peginterferon Alfa-2b (PEG-Intron) The serum concentration of Fluoxetine can be decreased when it is combined with Peginterferon alfa-2b. |
Pramlintide Injection | Pramlintide Injection The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Pramlintide. |
Sodium Oxybate | Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Exenatide Injection | Exenatide Injection The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Exenatide. |
Ibandronate | Ibandronate The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ibandronate. |
Isocarboxazid | Isocarboxazid The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Isocarboxazid. |
Ramelteon | Ramelteon Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon. |
Darifenacin | Darifenacin The serum concentration of Darifenacin can be increased when it is combined with Fluoxetine. |
Fentanyl | Fentanyl The risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Fluoxetine. |
Pregabalin | Pregabalin The therapeutic efficacy of Fluoxetine can be increased when used in combination with Pregabalin. |
Deferasirox | Deferasirox The serum concentration of Fluoxetine can be increased when it is combined with Deferasirox. |
Phenylephrine | Phenylephrine The metabolism of Fluoxetine can be increased when combined with Phenylephrine. |
Tipranavir | Tipranavir The serum concentration of Tipranavir can be increased when it is combined with Fluoxetine. |
Felbamate | Felbamate Felbamate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Insulin Detemir (rDNA Origin) Injection | Insulin Detemir (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Insulin detemir. |
Ranolazine | Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Fluoxetine. |
Abatacept Injection | Abatacept Injection The metabolism of Fluoxetine can be increased when combined with Abatacept. |
Rasagiline | Rasagiline The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Fluoxetine. |
Imatinib | Imatinib The serum concentration of Imatinib can be increased when it is combined with Fluoxetine. |
Sitagliptin | Sitagliptin The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Sitagliptin. |
Gefitinib | Gefitinib The serum concentration of Gefitinib can be increased when it is combined with Fluoxetine. |
Albuterol | Albuterol The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Salbutamol. |
Paliperidone | Paliperidone The serum concentration of Paliperidone can be increased when it is combined with Fluoxetine. |
Bortezomib | Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Fluoxetine. |
Insulin Glulisine (rDNA origin) Injection | Insulin Glulisine (rDNA origin) Injection The metabolism of Fluoxetine can be increased when combined with Insulin glulisine. |
Lubiprostone | Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Fluoxetine. |
Oxaliplatin Injection | Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Fluoxetine. |
Posaconazole | Posaconazole The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Posaconazole. |
Primaquine | Primaquine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Fluoxetine. |
Pemetrexed Injection | Pemetrexed Injection The metabolism of Pemetrexed can be decreased when combined with Fluoxetine. |
Dimenhydrinate | Dimenhydrinate Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Lisdexamfetamine | Lisdexamfetamine The serum concentration of Lisdexamfetamine can be increased when it is combined with Fluoxetine. |
Nabilone | Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Vorinostat | Vorinostat The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Vorinostat. |
Sorafenib | Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Fluoxetine. |
Sunitinib | Sunitinib The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Sunitinib. |
Dronabinol | Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Lapatinib | Lapatinib The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Lapatinib. |
Levocetirizine | Levocetirizine Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Dasatinib | Dasatinib The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Dasatinib. |
Mexiletine | Mexiletine The serum concentration of Mexiletine can be increased when it is combined with Fluoxetine. |
Armodafinil | Armodafinil The metabolism of Fluoxetine can be decreased when combined with Armodafinil. |
Paclitaxel (with polyoxyethylated castor oil) Injection | Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Fluoxetine. |
Temsirolimus | Temsirolimus The metabolism of Fluoxetine can be decreased when combined with Temsirolimus. |
Nilotinib | Nilotinib The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Nilotinib. |
Toremifene | Toremifene The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Toremifene. |
Bexarotene | Bexarotene The metabolism of Bexarotene can be decreased when combined with Fluoxetine. |
Chloramphenicol Injection | Chloramphenicol Injection The metabolism of Fluoxetine can be decreased when combined with Chloramphenicol. |
Desmopressin | Desmopressin The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Desmopressin. |
Betaine | Betaine The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Glycine betaine. |
OnabotulinumtoxinA Injection | OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Fluoxetine is combined with Botulinum toxin type A. |
RimabotulinumtoxinB Injection | RimabotulinumtoxinB Injection Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type B. |
Etravirine | Etravirine The metabolism of Etravirine can be decreased when combined with Fluoxetine. |
Arsenic Trioxide Injection | Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Arsenic trioxide. |
Desvenlafaxine | Desvenlafaxine The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Desvenlafaxine. |
Cevimeline | Cevimeline The serum concentration of Cevimeline can be increased when it is combined with Fluoxetine. |
Nebivolol | Nebivolol The serum concentration of Nebivolol can be increased when it is combined with Fluoxetine. |
Tretinoin | Tretinoin The metabolism of Tretinoin can be decreased when combined with Fluoxetine. |
Bendamustine Injection | Bendamustine Injection The metabolism of Bendamustine can be decreased when combined with Fluoxetine. |
Flecainide | Flecainide The serum concentration of Flecainide can be increased when it is combined with Fluoxetine. |
Certolizumab Injection | Certolizumab Injection The metabolism of Fluoxetine can be increased when combined with Certolizumab pegol. |
Irinotecan Injection | Irinotecan Injection The metabolism of Irinotecan can be decreased when combined with Fluoxetine. |
Praziquantel | Praziquantel The metabolism of Praziquantel can be decreased when combined with Fluoxetine. |
Rufinamide | Rufinamide Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Midazolam | Midazolam The serum concentration of Fluoxetine can be increased when it is combined with Midazolam. |
Naltrexone Injection | Naltrexone Injection The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Naltrexone. |
Eltrombopag | Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Fluoxetine. |
Milnacipran | Milnacipran The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Milnacipran. |
Dexlansoprazole | Dexlansoprazole The metabolism of Dexlansoprazole can be decreased when combined with Fluoxetine. |
Sodium Phosphate | Sodium Phosphate The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Fluoxetine. |
Fesoterodine | Fesoterodine The serum concentration of Fesoterodine can be increased when it is combined with Fluoxetine. |
Degarelix Injection | Degarelix Injection The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Degarelix. |
Betaxolol | Betaxolol The serum concentration of Betaxolol can be increased when it is combined with Fluoxetine. |
Iloperidone | Iloperidone The serum concentration of Fluoxetine can be increased when it is combined with Iloperidone. |
Prasugrel | Prasugrel The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Prasugrel. |
Lacosamide | Lacosamide Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Lacosamide. |
Everolimus | Everolimus The metabolism of Fluoxetine can be decreased when combined with Everolimus. |
Dronedarone | Dronedarone Fluoxetine may increase the QTc-prolonging activities of Dronedarone. |
AbobotulinumtoxinA Injection | AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Fluoxetine is combined with Botulinum toxin type A. |
Palonosetron Injection | Palonosetron Injection The serum concentration of Palonosetron can be increased when it is combined with Fluoxetine. |
Saxagliptin | Saxagliptin The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Saxagliptin. |
Telavancin Injection | Telavancin Injection The risk or severity of QTc prolongation can be increased when Telavancin is combined with Fluoxetine. |
Romidepsin Injection | Romidepsin Injection The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Romidepsin. |
Tapentadol | Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Golimumab Injection | Golimumab Injection The metabolism of Fluoxetine can be increased when combined with Golimumab. |
Pazopanib | Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Fluoxetine. |
Asenapine | Asenapine The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Asenapine. |
Vigabatrin | Vigabatrin Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Pitavastatin | Pitavastatin The metabolism of Pitavastatin can be decreased when combined with Fluoxetine. |
Albendazole | Albendazole The metabolism of Albendazole can be decreased when combined with Fluoxetine. |
Oxymorphone | Oxymorphone The serum concentration of Oxymorphone can be increased when it is combined with Fluoxetine. |
Dabigatran | Dabigatran The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Dabigatran. |
Liraglutide Injection | Liraglutide Injection The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Liraglutide. |
Tocilizumab Injection | Tocilizumab Injection The metabolism of Fluoxetine can be increased when combined with Tocilizumab. |
Dalfampridine | Dalfampridine The risk or severity of seizure can be increased when Fluoxetine is combined with Dalfampridine. |
Fingolimod | Fingolimod The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Fingolimod. |
Eribulin Injection | Eribulin Injection The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Eribulin. |
IncobotulinumtoxinA Injection | IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Fluoxetine is combined with Botulinum toxin type A. |
Lurasidone | Lurasidone The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Lurasidone. |
Acetaminophen Injection | Acetaminophen Injection The serum concentration of Acetaminophen can be increased when it is combined with Fluoxetine. |
Vilazodone | Vilazodone The serum concentration of Vilazodone can be increased when it is combined with Fluoxetine. |
Terbutaline Injection | Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Fluoxetine. |
Linagliptin | Linagliptin The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Linagliptin. |
Rilpivirine | Rilpivirine The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Fluoxetine. |
Potassium Iodide | Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Fluoxetine. |
Cyclophosphamide Injection | Cyclophosphamide Injection The metabolism of Cyclophosphamide can be decreased when combined with Fluoxetine. |
Abiraterone | Abiraterone The serum concentration of Fluoxetine can be increased when it is combined with Abiraterone. |
Triptorelin Injection | Triptorelin Injection The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Triptorelin. |
Rivaroxaban | Rivaroxaban The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Rivaroxaban. |
Ticagrelor | Ticagrelor The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Ticagrelor. |
Vandetanib | Vandetanib The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Vandetanib. |
Clobazam | Clobazam The serum concentration of Fluoxetine can be increased when it is combined with Clobazam. |
Vemurafenib | Vemurafenib The serum concentration of Fluoxetine can be increased when it is combined with Vemurafenib. |
Vismodegib | Vismodegib The metabolism of Vismodegib can be decreased when combined with Fluoxetine. |
Axitinib | Axitinib The metabolism of Axitinib can be decreased when combined with Fluoxetine. |
Crizotinib | Crizotinib The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Fluoxetine. |
Cabergoline | Cabergoline The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Fluoxetine. |
Fondaparinux Injection | Fondaparinux Injection The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Fondaparinux. |
Ezogabine | Ezogabine Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Iloprost | Iloprost The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Iloprost. |
Enzalutamide | Enzalutamide The metabolism of Enzalutamide can be increased when combined with Fluoxetine. |
Mirabegron | Mirabegron The serum concentration of Mirabegron can be increased when it is combined with Fluoxetine. |
Regorafenib | Regorafenib The metabolism of Fluoxetine can be decreased when combined with Regorafenib. |
Linaclotide | Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Fluoxetine. |
Teriflunomide | Teriflunomide The serum concentration of Fluoxetine can be decreased when it is combined with Teriflunomide. |
Lorcaserin | Lorcaserin The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Mecasermin. |
Cabozantinib (thyroid cancer) | Cabozantinib (thyroid cancer) The metabolism of Cabozantinib can be decreased when combined with Fluoxetine. |
Bedaquiline | Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Fluoxetine. |
Icosapent Ethyl | Icosapent Ethyl The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Icosapent ethyl. |
Alogliptin | Alogliptin The serum concentration of Alogliptin can be increased when it is combined with Fluoxetine. |
Ponatinib | Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Fluoxetine. |
Pomalidomide | Pomalidomide Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Apixaban | Apixaban The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Apixaban. |
Canagliflozin | Canagliflozin The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Canagliflozin. |
Dabrafenib | Dabrafenib The serum concentration of Fluoxetine can be decreased when it is combined with Dabrafenib. |
Ospemifene | Ospemifene The metabolism of Ospemifene can be decreased when combined with Fluoxetine. |
Levomilnacipran | Levomilnacipran The serum concentration of Levomilnacipran can be increased when it is combined with Fluoxetine. |
Vortioxetine | Vortioxetine The serum concentration of Vortioxetine can be increased when it is combined with Fluoxetine. |
Perampanel | Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Ibrutinib | Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Fluoxetine. |
Ketorolac Injection | Ketorolac Injection The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Ketorolac. |
Simeprevir | Simeprevir The metabolism of Fluoxetine can be decreased when combined with Simeprevir. |
Dapagliflozin | Dapagliflozin The serum concentration of Dapagliflozin can be increased when it is combined with Fluoxetine. |
Apremilast | Apremilast The metabolism of Fluoxetine can be increased when combined with Apremilast. |
Ceritinib | Ceritinib The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Fluoxetine. |
Siltuximab Injection | Siltuximab Injection The metabolism of Fluoxetine can be increased when combined with Siltuximab. |
Albiglutide Injection | Albiglutide Injection The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Albiglutide. |
Eslicarbazepine | Eslicarbazepine Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Belinostat Injection | Belinostat Injection The metabolism of Fluoxetine can be increased when combined with Belinostat. |
Testosterone Injection | Testosterone Injection The metabolism of Testosterone can be decreased when combined with Fluoxetine. |
Oritavancin Injection | Oritavancin Injection The metabolism of Fluoxetine can be decreased when combined with Oritavancin. |
Empagliflozin | Empagliflozin The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Empagliflozin. |
Vorapaxar | Vorapaxar The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Vorapaxar. |
Hydrocodone | Hydrocodone Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
Suvorexant | Suvorexant Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
Dulaglutide Injection | Dulaglutide Injection The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Dulaglutide. |
Edoxaban | Edoxaban The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Edoxaban. |
Peginterferon Beta-1a Injection | Peginterferon Beta-1a Injection The metabolism of Fluoxetine can be decreased when combined with Peginterferon beta-1a. |
Olaparib | Olaparib The metabolism of Olaparib can be increased when combined with Fluoxetine. |
Methamphetamine | Methamphetamine The serum concentration of Metamfetamine can be increased when it is combined with Fluoxetine. |
Tasimelteon | Tasimelteon Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Lanreotide Injection | Lanreotide Injection The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Lanreotide. |
Pirfenidone | Pirfenidone The metabolism of Fluoxetine can be decreased when combined with Pirfenidone. |
Secukinumab Injection | Secukinumab Injection The metabolism of Fluoxetine can be increased when combined with Secukinumab. |
Risperidone Injection | Risperidone Injection The serum concentration of Risperidone can be increased when it is combined with Fluoxetine. |
Insulin Human Inhalation | Insulin Human Inhalation The metabolism of Fluoxetine can be increased when combined with Insulin human. |
Lenvatinib | Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Fluoxetine. |
Naloxegol | Naloxegol The metabolism of Fluoxetine can be decreased when combined with Naloxegol. |
Panobinostat | Panobinostat The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Fluoxetine. |
Haloperidol Injection | Haloperidol Injection The metabolism of Haloperidol can be decreased when combined with Fluoxetine. |
Ivabradine | Ivabradine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ivabradine. |
Flibanserin | Flibanserin The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Flibanserin. |
Rolapitant | Rolapitant The metabolism of Fluoxetine can be decreased when combined with Rolapitant. |
Brexpiprazole | Brexpiprazole The serum concentration of Brexpiprazole can be increased when it is combined with Fluoxetine. |
Ziprasidone Injection | Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Fluoxetine. |
Cariprazine | Cariprazine The serum concentration of Cariprazine can be increased when it is combined with Fluoxetine. |
Eluxadoline | Eluxadoline The risk or severity of constipation can be increased when Fluoxetine is combined with Eluxadoline. |
Insulin Degludec (rDNA Origin) Injection | Insulin Degludec (rDNA Origin) Injection The metabolism of Fluoxetine can be increased when combined with Insulin degludec. |
Trabectedin Injection | Trabectedin Injection The serum concentration of Trabectedin can be increased when it is combined with Fluoxetine. |
Osimertinib | Osimertinib The serum concentration of Fluoxetine can be decreased when it is combined with Osimertinib. |
Rifapentine | Rifapentine The metabolism of Fluoxetine can be increased when combined with Rifapentine. |
Lesinurad | Lesinurad The metabolism of Lesinurad can be decreased when combined with Fluoxetine. |
Dexamethasone Injection | Dexamethasone Injection The metabolism of Fluoxetine can be increased when combined with Dexamethasone. |
Defibrotide Injection | Defibrotide Injection The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Defibrotide. |
Brivaracetam Injection | Brivaracetam Injection Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Cobicistat | Cobicistat The metabolism of Fluoxetine can be decreased when combined with Cobicistat. |
Pimavanserin | Pimavanserin The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Pimavanserin. |
Obeticholic Acid | Obeticholic Acid The metabolism of Fluoxetine can be decreased when combined with Obeticholic acid. |
Diphenhydramine Injection | Diphenhydramine Injection The serum concentration of Diphenhydramine can be increased when it is combined with Fluoxetine. |
Rucaparib | Rucaparib The serum concentration of Rucaparib can be increased when it is combined with Fluoxetine. |
Lixisenatide Injection | Lixisenatide Injection The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Lixisenatide. |
Ribociclib | Ribociclib The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ribociclib. |
Parathyroid Hormone Injection | Parathyroid Hormone Injection The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Fluoxetine. |
Doxepin (Insomnia) | Doxepin (Insomnia) The serum concentration of Doxepin can be increased when it is combined with Fluoxetine. |
Plecanatide | Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Fluoxetine. |
Deutetrabenazine | Deutetrabenazine The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Fluoxetine. |
Valbenazine | Valbenazine The serum concentration of Valbenazine can be increased when it is combined with Fluoxetine. |
Safinamide | Safinamide The risk or severity of serotonin syndrome can be increased when Safinamide is combined with Fluoxetine. |
Midostaurin | Midostaurin The metabolism of Fluoxetine can be decreased when combined with Midostaurin. |
Abaloparatide Injection | Abaloparatide Injection The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Fluoxetine. |
Enasidenib | Enasidenib The serum concentration of Enasidenib can be increased when it is combined with Fluoxetine. |
Delafloxacin | Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Fluoxetine. |
Betrixaban | Betrixaban The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Betrixaban. |
Letermovir | Letermovir The serum concentration of Letermovir can be increased when it is combined with Fluoxetine. |
Semaglutide Injection | Semaglutide Injection The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Semaglutide. |
Tetrabenazine | Tetrabenazine The serum concentration of Tetrabenazine can be increased when it is combined with Fluoxetine. |
Ertugliflozin | Ertugliflozin The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Ertugliflozin. |
Buprenorphine Injection | Buprenorphine Injection Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Apalutamide | Apalutamide The serum concentration of Fluoxetine can be increased when it is combined with Apalutamide. |
Avatrombopag | Avatrombopag The metabolism of Fluoxetine can be increased when combined with Avatrombopag. |
Lofexidine | Lofexidine The therapeutic efficacy of Fluoxetine can be increased when used in combination with Lofexidine. |
Eliglustat | Eliglustat The serum concentration of Eliglustat can be increased when it is combined with Fluoxetine. |
Encorafenib | Encorafenib The serum concentration of Encorafenib can be increased when it is combined with Fluoxetine. |
Binimetinib | Binimetinib The metabolism of Binimetinib can be decreased when combined with Fluoxetine. |
Ivosidenib | Ivosidenib The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Fluoxetine. |
Elagolix | Elagolix The serum concentration of Elagolix can be increased when it is combined with Fluoxetine. |
Tafenoquine | Tafenoquine The serum concentration of Tafenoquine can be increased when it is combined with Fluoxetine. |
Cannabidiol | Cannabidiol The risk or severity of serotonin syndrome can be increased when Cannabidiol is combined with Fluoxetine. |
Dacomitinib | Dacomitinib The serum concentration of Dacomitinib can be increased when it is combined with Fluoxetine. |
Stiripentol | Stiripentol Stiripentol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Gilteritinib | Gilteritinib The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Gilteritinib. |
Glasdegib | Glasdegib The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Glasdegib. |
Lorlatinib | Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Fluoxetine. |
Rifamycin | Rifamycin The metabolism of Rifamycin can be increased when combined with Fluoxetine. |
Prucalopride | Prucalopride The therapeutic efficacy of Prucalopride can be decreased when used in combination with Fluoxetine. |
Magnesium Citrate | Magnesium Citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Fluoxetine. |
Emapalumab-lzsg Injection | Emapalumab-lzsg Injection The metabolism of Fluoxetine can be increased when combined with Emapalumab. |
Siponimod | Siponimod The risk or severity of adverse effects can be increased when Fluoxetine is combined with Siponimod. |
Acyclovir Ophthalmic | Acyclovir Ophthalmic The metabolism of Acyclovir can be decreased when combined with Fluoxetine. |
Caplacizumab-yhdp Injection | Caplacizumab-yhdp Injection The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Caplacizumab. |
Erdafitinib | Erdafitinib The metabolism of Erdafitinib can be decreased when combined with Fluoxetine. |
Esomeprazole Injection | Esomeprazole Injection The metabolism of Esomeprazole can be decreased when combined with Fluoxetine. |
Alpelisib | Alpelisib The serum concentration of Fluoxetine can be decreased when it is combined with Alpelisib. |
Brexanolone Injection | Brexanolone Injection Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Solriamfetol | Solriamfetol Solriamfetol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Triclabendazole | Triclabendazole The metabolism of Fluoxetine can be decreased when combined with Triclabendazole. |
Entrectinib | Entrectinib The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Entrectinib. |
Istradefylline | Istradefylline The serum concentration of Istradefylline can be increased when it is combined with Fluoxetine. |
Pitolisant | Pitolisant The serum concentration of Pitolisant can be increased when it is combined with Fluoxetine. |
Fedratinib | Fedratinib The metabolism of Fedratinib can be decreased when combined with Fluoxetine. |
Lefamulin | Lefamulin Fluoxetine may increase the QTc-prolonging activities of Lefamulin. |
Phenytoin Injection | Phenytoin Injection The risk or severity of Anticonvulsant Toxicity can be increased when Fluoxetine is combined with Phenytoin. |
Fosphenytoin Injection | Fosphenytoin Injection The risk or severity of Anticonvulsant Toxicity can be increased when Fluoxetine is combined with Fosphenytoin. |
Zanubrutinib | Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Fluoxetine. |
Voxelotor | Voxelotor The metabolism of Voxelotor can be decreased when combined with Fluoxetine. |
Avapritinib | Avapritinib The metabolism of Avapritinib can be decreased when combined with Fluoxetine. |
Lumateperone | Lumateperone Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Lasmiditan | Lasmiditan The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Fluoxetine. |
Cenobamate | Cenobamate The serum concentration of Cenobamate can be decreased when it is combined with Fluoxetine. |
Selumetinib | Selumetinib The metabolism of Selumetinib can be decreased when combined with Fluoxetine. |
Selpercatinib | Selpercatinib The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Selpercatinib. |
Capmatinib | Capmatinib The metabolism of Fluoxetine can be decreased when combined with Capmatinib. |
Lemborexant | Lemborexant The serum concentration of Fluoxetine can be decreased when it is combined with Lemborexant. |
Fenfluramine | Fenfluramine The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Fenfluramine. |
Octreotide | Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluoxetine. |
Pralsetinib | Pralsetinib The metabolism of Fluoxetine can be decreased when combined with Pralsetinib. |
Satralizumab-mwge Injection | Satralizumab-mwge Injection The serum concentration of Fluoxetine can be decreased when it is combined with Satralizumab. |
Viloxazine | Viloxazine Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Viloxazine. |
Theophylline | Theophylline The serum concentration of Theophylline can be increased when it is combined with Fluoxetine. |
Fenoprofen | Fenoprofen The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Fenoprofen. |
Indomethacin | Indomethacin The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Indomethacin. |
Mefenamic Acid | Mefenamic Acid The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Mefenamic acid. |
Naproxen | Naproxen The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Naproxen. |
Tolmetin | Tolmetin The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Tolmetin. |
Sulindac | Sulindac The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Sulindac. |
Trazodone | Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Fluoxetine. |
Hydroxyurea | Hydroxyurea The metabolism of Fluoxetine can be decreased when combined with Hydroxyurea. |
Floxuridine | Floxuridine The metabolism of Fluoxetine can be decreased when combined with Floxuridine. |
Phenobarbital | Phenobarbital Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital. |
Metaxalone | Metaxalone The risk or severity of serotonin syndrome can be increased when Metaxalone is combined with Fluoxetine. |
Levorphanol | Levorphanol The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Fluoxetine. |
Primidone | Primidone Primidone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Methsuximide | Methsuximide Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide. |
Diethylpropion | Diethylpropion The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Diethylpropion. |
Chlorpromazine | Chlorpromazine The serum concentration of Chlorpromazine can be increased when it is combined with Fluoxetine. |
Diazepam | Diazepam The serum concentration of Diazepam can be increased when it is combined with Fluoxetine. |
Oxazepam | Oxazepam The serum concentration of Oxazepam can be increased when it is combined with Fluoxetine. |
Flurazepam | Flurazepam The serum concentration of Flurazepam can be increased when it is combined with Fluoxetine. |
Clorazepate | Clorazepate The serum concentration of Clorazepic acid can be increased when it is combined with Fluoxetine. |
Lorazepam | Lorazepam The serum concentration of Fluoxetine can be increased when it is combined with Lorazepam. |
Carmustine | Carmustine The metabolism of Fluoxetine can be decreased when combined with Carmustine. |
Amantadine | Amantadine The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Amantadine. |
Codeine | Codeine The serum concentration of Codeine can be increased when it is combined with Fluoxetine. |
Meprobamate | Meprobamate Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Chlordiazepoxide | Chlordiazepoxide The serum concentration of Chlordiazepoxide can be increased when it is combined with Fluoxetine. |
Bromocriptine | Bromocriptine Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine. |
Tranylcypromine | Tranylcypromine The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Tranylcypromine. |
Phenelzine | Phenelzine The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Phenelzine. |
Procarbazine | Procarbazine The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Fluoxetine. |
Ergoloid Mesylates | Ergoloid Mesylates The risk or severity of serotonin syndrome can be increased when Ergoloid mesylate is combined with Fluoxetine. |
Minocycline | Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Prochlorperazine | Prochlorperazine The serum concentration of Fluoxetine can be increased when it is combined with Prochlorperazine. |
Thioridazine | Thioridazine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Thioridazine. |
Trifluoperazine | Trifluoperazine Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine. |
Dapsone | Dapsone The metabolism of Fluoxetine can be decreased when combined with Dapsone. |
Sulfadiazine | Sulfadiazine The metabolism of Fluoxetine can be decreased when combined with Sulfadiazine. |
Oxycodone | Oxycodone The serum concentration of Oxycodone can be increased when it is combined with Fluoxetine. |
Methadone | Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Fluoxetine. |
Oxybutynin | Oxybutynin The metabolism of Oxybutynin can be decreased when combined with Fluoxetine. |
Benztropine | Benztropine The serum concentration of Benzatropine can be increased when it is combined with Fluoxetine. |
Maprotiline | Maprotiline The serum concentration of Maprotiline can be increased when it is combined with Fluoxetine. |
Ibuprofen | Ibuprofen The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Ibuprofen. |
Trihexyphenidyl | Trihexyphenidyl Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl. |
Orphenadrine | Orphenadrine Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
Perphenazine | Perphenazine The serum concentration of Perphenazine can be increased when it is combined with Fluoxetine. |
Azathioprine | Azathioprine The metabolism of Azathioprine can be decreased when combined with Fluoxetine. |
Fluphenazine | Fluphenazine Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine. |
Phentermine | Phentermine The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Fluoxetine. |
Amoxapine | Amoxapine The serum concentration of Amoxapine can be increased when it is combined with Fluoxetine. |
Sulfasalazine | Sulfasalazine The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Sulfasalazine. |
Hydrocortisone | Hydrocortisone The metabolism of Hydrocortisone can be increased when combined with Fluoxetine. |
Doxorubicin | Doxorubicin The metabolism of Fluoxetine can be decreased when combined with Doxorubicin. |
Mechlorethamine | Mechlorethamine The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Mechlorethamine. |
Pyridostigmine | Pyridostigmine The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Pyridostigmine. |
Carbamazepine | Carbamazepine The serum concentration of Carbamazepine can be increased when it is combined with Fluoxetine. |
Molindone | Molindone Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Molindone. |
Clonidine | Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Fluoxetine. |
Cimetidine | Cimetidine The metabolism of Cimetidine can be decreased when combined with Fluoxetine. |
Warfarin | Warfarin The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Warfarin. |
Clonazepam | Clonazepam The serum concentration of Fluoxetine can be increased when it is combined with Clonazepam. |
Loperamide | Loperamide The serum concentration of Fluoxetine can be increased when it is combined with Loperamide. |
Promethazine | Promethazine The serum concentration of Promethazine can be increased when it is combined with Fluoxetine. |
Meclofenamate | Meclofenamate The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Meclofenamic acid. |
Griseofulvin | Griseofulvin The metabolism of Fluoxetine can be increased when combined with Griseofulvin. |
Digoxin | Digoxin The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Digoxin. |
Loxapine | Loxapine The risk or severity of serotonin syndrome can be increased when Loxapine is combined with Fluoxetine. |
Chloroquine | Chloroquine The serum concentration of Chloroquine can be increased when it is combined with Fluoxetine. |
Quinine | Quinine The serum concentration of Quinine can be increased when it is combined with Fluoxetine. |
Ethosuximide | Ethosuximide Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide. |
Triamterene | Triamterene The metabolism of Fluoxetine can be decreased when combined with Triamterene. |
Lactulose | Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Fluoxetine. |
Sulfinpyrazone | Sulfinpyrazone The metabolism of Sulfinpyrazone can be decreased when combined with Fluoxetine. |
Chlorothiazide | Chlorothiazide The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Chlorothiazide. |
Chlorthalidone | Chlorthalidone The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Chlorthalidone. |
Metolazone | Metolazone The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Metolazone. |
Secobarbital | Secobarbital Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Desipramine | Desipramine The serum concentration of Desipramine can be increased when it is combined with Fluoxetine. |
Amitriptyline | Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Fluoxetine. |
Imipramine | Imipramine The serum concentration of Fluoxetine can be increased when it is combined with Imipramine. |
Probenecid | Probenecid The metabolism of Fluoxetine can be decreased when combined with Probenecid. |
Quinidine | Quinidine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Quinidine. |
Procainamide | Procainamide The serum concentration of Procainamide can be increased when it is combined with Fluoxetine. |
Isoniazid | Isoniazid The risk or severity of serotonin syndrome can be increased when Isoniazid is combined with Fluoxetine. |
Rifampin | Rifampin The metabolism of Fluoxetine can be increased when combined with Rifampicin. |
Disopyramide | Disopyramide The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Fluoxetine. |
Valproic Acid | Valproic Acid The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Fluoxetine. |
Tamoxifen | Tamoxifen The serum concentration of Tamoxifen can be increased when it is combined with Fluoxetine. |
Butabarbital | Butabarbital Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Levothyroxine | Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fluoxetine. |
Liothyronine | Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluoxetine. |
Methimazole | Methimazole The metabolism of Fluoxetine can be decreased when combined with Methimazole. |
Propylthiouracil | Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Fluoxetine. |
Chlorpropamide | Chlorpropamide The metabolism of Chlorpropamide can be decreased when combined with Fluoxetine. |
Tolbutamide | Tolbutamide The metabolism of Tolbutamide can be decreased when combined with Fluoxetine. |
Tolazamide | Tolazamide The metabolism of Tolazamide can be decreased when combined with Fluoxetine. |
Dextromethorphan | Dextromethorphan The serum concentration of Dextromethorphan can be increased when it is combined with Fluoxetine. |
Cyclobenzaprine | Cyclobenzaprine The risk or severity of CNS depression can be increased when Fluoxetine is combined with Cyclobenzaprine. |
Niacin | Niacin The metabolism of Fluoxetine can be decreased when combined with Niacin. |
Baclofen | Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Doxylamine | Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Cyproheptadine | Cyproheptadine Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Clemastine | Clemastine Clemastine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Chlorpheniramine | Chlorpheniramine The serum concentration of Chlorpheniramine can be increased when it is combined with Fluoxetine. |
Brompheniramine | Brompheniramine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Meclizine | Meclizine The serum concentration of Meclizine can be increased when it is combined with Fluoxetine. |
Methyclothiazide | Methyclothiazide The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Methyclothiazide. |
Hydrochlorothiazide | Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Hydrochlorothiazide. |
Dantrolene | Dantrolene Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Chlorzoxazone | Chlorzoxazone The serum concentration of Chlorzoxazone can be increased when it is combined with Fluoxetine. |
Carisoprodol | Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluoxetine. |
Methocarbamol | Methocarbamol Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Disulfiram | Disulfiram The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Disulfiram. |
Propranolol (Cardiovascular) | Propranolol (Cardiovascular) The serum concentration of Propranolol can be increased when it is combined with Fluoxetine. |
Pseudoephedrine | Pseudoephedrine The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Pseudoephedrine. |
Nortriptyline | Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Fluoxetine. |
Nadolol | Nadolol The serum concentration of Nadolol can be increased when it is combined with Fluoxetine. |
Butorphanol Injection | Butorphanol Injection The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Fluoxetine. |
Nalbuphine Injection | Nalbuphine Injection The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Fluoxetine. |
Oxytocin Injection | Oxytocin Injection The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Oxytocin. |
Trimethobenzamide | Trimethobenzamide Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Flavoxate | Flavoxate Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate. |
Papaverine | Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Fluoxetine. |
Fluorouracil Injection | Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Fluoxetine. |
Dacarbazine | Dacarbazine The metabolism of Dacarbazine can be decreased when combined with Fluoxetine. |
Acetazolamide | Acetazolamide Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Calcitonin Salmon Injection | Calcitonin Salmon Injection The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Fluoxetine. |
Ketoconazole | Ketoconazole The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Fluoxetine. |
Pyrantel | Pyrantel Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Thiotepa Injection | Thiotepa Injection The metabolism of Fluoxetine can be decreased when combined with Thiotepa. |
Dipyridamole | Dipyridamole The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Dipyridamole. |
Vinblastine | Vinblastine The metabolism of Fluoxetine can be decreased when combined with Vinblastine. |
Metoprolol | Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Fluoxetine. |
Hydroxyzine | Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Fluoxetine. |
Thiothixene | Thiothixene Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene. |
Aspirin | Aspirin The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Acetylsalicylic acid. |
Salsalate | Salsalate The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Salsalate. |
Alprazolam | Alprazolam The serum concentration of Fluoxetine can be increased when it is combined with Alprazolam. |
Temazepam | Temazepam The serum concentration of Fluoxetine can be increased when it is combined with Temazepam. |
Triazolam | Triazolam The serum concentration of Triazolam can be increased when it is combined with Fluoxetine. |
Dicyclomine | Dicyclomine Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine. |
Hyoscyamine | Hyoscyamine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Hyoscyamine. |
Propantheline | Propantheline Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Propantheline. |
Trimethoprim | Trimethoprim The metabolism of Trimethoprim can be decreased when combined with Fluoxetine. |
Diltiazem | Diltiazem The serum concentration of Diltiazem can be increased when it is combined with Fluoxetine. |
Nifedipine | Nifedipine The serum concentration of Fluoxetine can be increased when it is combined with Nifedipine. |
Timolol | Timolol The metabolism of Timolol can be decreased when combined with Fluoxetine. |
Verapamil | Verapamil The metabolism of Verapamil can be decreased when combined with Fluoxetine. |
Atenolol | Atenolol The serum concentration of Atenolol can be increased when it is combined with Fluoxetine. |
Pindolol | Pindolol The serum concentration of Pindolol can be increased when it is combined with Fluoxetine. |
Cisplatin Injection | Cisplatin Injection The metabolism of Fluoxetine can be decreased when combined with Cisplatin. |
Diflunisal | Diflunisal The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Diflunisal. |
Piroxicam | Piroxicam The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Piroxicam. |
Streptozocin | Streptozocin The metabolism of Fluoxetine can be increased when combined with Streptozocin. |
Etoposide | Etoposide The metabolism of Etoposide can be decreased when combined with Fluoxetine. |
Glyburide | Glyburide The metabolism of Glyburide can be decreased when combined with Fluoxetine. |
Glipizide | Glipizide The metabolism of Glipizide can be decreased when combined with Fluoxetine. |
Indapamide | Indapamide The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Indapamide. |
Nafcillin Injection | Nafcillin Injection The metabolism of Fluoxetine can be increased when combined with Nafcillin. |
Pentoxifylline | Pentoxifylline The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Pentoxifylline. |
Pentamidine Injection | Pentamidine Injection The serum concentration of Pentamidine can be increased when it is combined with Fluoxetine. |
Labetalol | Labetalol The serum concentration of Labetalol can be increased when it is combined with Fluoxetine. |
Leuprolide Injection | Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fluoxetine. |
Gemfibrozil | Gemfibrozil The metabolism of Fluoxetine can be decreased when combined with Gemfibrozil. |
Guanabenz | Guanabenz The metabolism of Guanabenz can be decreased when combined with Fluoxetine. |
Ketoprofen | Ketoprofen The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Ketoprofen. |
Pimozide | Pimozide Fluoxetine may increase the QTc-prolonging activities of Pimozide. |
Flurbiprofen | Flurbiprofen The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Flurbiprofen. |
Amiodarone | Amiodarone The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Fluoxetine. |
Buspirone | Buspirone The serum concentration of Buspirone can be increased when it is combined with Fluoxetine. |
Lovastatin | Lovastatin The metabolism of Fluoxetine can be decreased when combined with Lovastatin. |
Ciprofloxacin | Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Fluoxetine. |
Mesalamine | Mesalamine The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Mesalazine. |
Diclofenac | Diclofenac The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Diclofenac. |
Nimodipine | Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Fluoxetine. |
Interferon Alfa-2b Injection | Interferon Alfa-2b Injection The metabolism of Fluoxetine can be decreased when combined with Interferon alfa-2b. |
Clozapine | Clozapine The serum concentration of Fluoxetine can be increased when it is combined with Clozapine. |
Estazolam | Estazolam The serum concentration of Estazolam can be increased when it is combined with Fluoxetine. |
Idarubicin | Idarubicin The serum concentration of Idarubicin can be increased when it is combined with Fluoxetine. |
Ofloxacin | Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Fluoxetine. |
Clarithromycin | Clarithromycin The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Fluoxetine. |
Etodolac | Etodolac The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Etodolac. |
Felodipine | Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Fluoxetine. |
Nabumetone | Nabumetone The risk or severity of gastrointestinal bleeding can be increased when Nabumetone is combined with Fluoxetine. |
Simvastatin | Simvastatin The serum concentration of Fluoxetine can be increased when it is combined with Simvastatin. |
Amlodipine | Amlodipine The risk or severity of QTc prolongation can be increased when Amlodipine is combined with Fluoxetine. |
Teniposide Injection | Teniposide Injection The metabolism of Fluoxetine can be decreased when combined with Teniposide. |
Itraconazole | Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Fluoxetine. |
Oxaprozin | Oxaprozin The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Oxaprozin. |
Atovaquone | Atovaquone The metabolism of Fluoxetine can be decreased when combined with Atovaquone. |
Rifabutin | Rifabutin The metabolism of Fluoxetine can be increased when combined with Rifabutin. |
Sotalol | Sotalol The serum concentration of Sotalol can be increased when it is combined with Fluoxetine. |
Bisoprolol | Bisoprolol The serum concentration of Bisoprolol can be increased when it is combined with Fluoxetine. |
Zolpidem | Zolpidem Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
Doxazosin | Doxazosin The serum concentration of Doxazosin can be increased when it is combined with Fluoxetine. |
Isradipine | Isradipine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Isradipine. |
Omeprazole | Omeprazole The metabolism of Omeprazole can be decreased when combined with Fluoxetine. |
Cisapride | Cisapride The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Cisapride. |
Gabapentin | Gabapentin Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin. |
Fluvastatin | Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Fluoxetine. |
Venlafaxine | Venlafaxine The serum concentration of Fluoxetine can be increased when it is combined with Venlafaxine. |
Nizatidine | Nizatidine The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Nizatidine. |
Fluvoxamine | Fluvoxamine The serum concentration of Fluoxetine can be increased when it is combined with Fluvoxamine. |
Nefazodone | Nefazodone The serum concentration of Nefazodone can be increased when it is combined with Fluoxetine. |
Lamotrigine | Lamotrigine Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine. |
Losartan | Losartan The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Losartan. |
Tramadol | Tramadol The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Tramadol. |
Vinorelbine Injection | Vinorelbine Injection The metabolism of Fluoxetine can be decreased when combined with Vinorelbine. |
Moexipril | Moexipril The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Moexipril. |
Lansoprazole | Lansoprazole The metabolism of Fluoxetine can be decreased when combined with Lansoprazole. |
Ifosfamide Injection | Ifosfamide Injection The metabolism of Ifosfamide can be decreased when combined with Fluoxetine. |
Nicardipine | Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Fluoxetine. |
Bupropion | Bupropion The risk or severity of seizure can be increased when Fluoxetine is combined with Bupropion. |
Ticlopidine | Ticlopidine The serum concentration of Ticlopidine can be increased when it is combined with Fluoxetine. |
Saquinavir | Saquinavir The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Fluoxetine. |
Metformin | Metformin The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Metformin. |
Dalteparin Injection | Dalteparin Injection The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Dalteparin. |
Riluzole | Riluzole Riluzole may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Acarbose | Acarbose The risk or severity of hypoglycemia can be increased when Acarbose is combined with Fluoxetine. |
Glimepiride | Glimepiride The metabolism of Glimepiride can be decreased when combined with Fluoxetine. |
Ritonavir | Ritonavir The serum concentration of Fluoxetine can be increased when it is combined with Ritonavir. |
Clomipramine | Clomipramine The serum concentration of Clomipramine can be increased when it is combined with Fluoxetine. |
Zafirlukast | Zafirlukast The metabolism of Fluoxetine can be decreased when combined with Zafirlukast. |
Mirtazapine | Mirtazapine Fluoxetine may increase the serotonergic activities of Mirtazapine. |
Topiramate | Topiramate Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Topiramate. |
Zileuton | Zileuton The metabolism of Zileuton can be decreased when combined with Fluoxetine. |
Valsartan | Valsartan The metabolism of Valsartan can be decreased when combined with Fluoxetine. |
Insulin Lispro Injection | Insulin Lispro Injection The metabolism of Fluoxetine can be increased when combined with Insulin lispro. |
Pramipexole | Pramipexole Fluoxetine may increase the sedative activities of Pramipexole. |
Donepezil | Donepezil The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Donepezil. |
Nelfinavir | Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Fluoxetine. |
Azithromycin | Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Fluoxetine. |
Loratadine | Loratadine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Loratadine. |
Carvedilol | Carvedilol The serum concentration of Carvedilol can be increased when it is combined with Fluoxetine. |
Nilutamide | Nilutamide The metabolism of Fluoxetine can be decreased when combined with Nilutamide. |
Flutamide | Flutamide The metabolism of Flutamide can be decreased when combined with Fluoxetine. |
Selegiline | Selegiline The serum concentration of Selegiline can be increased when it is combined with Fluoxetine. |
Bicalutamide | Bicalutamide The metabolism of Fluoxetine can be decreased when combined with Bicalutamide. |
Sertraline | Sertraline The serum concentration of Sertraline can be increased when it is combined with Fluoxetine. |
Propafenone | Propafenone The serum concentration of Fluoxetine can be increased when it is combined with Propafenone. |
Letrozole | Letrozole The metabolism of Fluoxetine can be decreased when combined with Letrozole. |
Raloxifene | Raloxifene The metabolism of Fluoxetine can be decreased when combined with Raloxifene. |
Irbesartan | Irbesartan The metabolism of Irbesartan can be decreased when combined with Fluoxetine. |
Tamsulosin | Tamsulosin The serum concentration of Tamsulosin can be increased when it is combined with Fluoxetine. |
Ropinirole | Ropinirole The risk or severity of adverse effects can be increased when Fluoxetine is combined with Ropinirole. |
Quetiapine | Quetiapine The serum concentration of Quetiapine can be increased when it is combined with Fluoxetine. |
Cetirizine | Cetirizine Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Paroxetine | Paroxetine The serum concentration of Paroxetine can be increased when it is combined with Fluoxetine. |
Tolcapone | Tolcapone Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Citalopram | Citalopram The serum concentration of Citalopram can be increased when it is combined with Fluoxetine. |
Capecitabine | Capecitabine The metabolism of Fluoxetine can be decreased when combined with Capecitabine. |
Efavirenz | Efavirenz Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Sildenafil | Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Fluoxetine. |
Pioglitazone | Pioglitazone The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Pioglitazone. |
Celecoxib | Celecoxib The risk or severity of bleeding can be increased when Celecoxib is combined with Fluoxetine. |
Rosiglitazone | Rosiglitazone The metabolism of Rosiglitazone can be decreased when combined with Fluoxetine. |
Tolterodine | Tolterodine The serum concentration of Tolterodine can be increased when it is combined with Fluoxetine. |
Thalidomide | Thalidomide Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
Balsalazide | Balsalazide The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Balsalazide. |
Nateglinide | Nateglinide The serum concentration of Nateglinide can be increased when it is combined with Fluoxetine. |
Galantamine | Galantamine The serum concentration of Fluoxetine can be increased when it is combined with Galantamine. |
Levetiracetam | Levetiracetam Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
Rabeprazole | Rabeprazole The metabolism of Rabeprazole can be decreased when combined with Fluoxetine. |
Terbinafine | Terbinafine The metabolism of Terbinafine can be decreased when combined with Fluoxetine. |
Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists